Filtered By:
Specialty: Cardiology
Source: European Heart Journal
Drug: Insulin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 6 results found since Jan 2013.

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500  000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk for cardiovascular (CV) events. Hyperglycaemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little to no impact on reducing CV risk, especially in patients with a long duration of T2D and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel class of anti-hyperglycaemic medications that increase urinary glucose excretion, thus improving glycaemic control independent of insulin. The recently published CV outc...
Source: European Heart Journal - November 16, 2016 Category: Cardiology Authors: Marx, N., McGuire, D. K. Tags: Clinical update Source Type: research

Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials
Conclusions</div>A small number of clinical variables identify a subset of patients with HF-PEF, but without AF, at elevated risk of stroke.</span>
Source: European Heart Journal - November 12, 2016 Category: Cardiology Source Type: research

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two- to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular ri...
Source: European Heart Journal - September 7, 2015 Category: Cardiology Authors: Ferrannini, E., DeFronzo, R. A. Tags: Clinical update Source Type: research

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Conclusion Severe hypoglycaemia is associated with an increased risk for CV outcomes in people at high CV risk and dysglycaemia. Although allocation to insulin glargine vs. standard care was associated with an increased risk of severe and non-severe hypoglycaemia, the relative risk of CV outcomes with hypoglycaemia was lower with insulin glargine-based glucose-lowering therapy than with the standard glycaemic control. Trial Registration (ORIGIN ClinicalTrials.gov number NCT00069784).
Source: European Heart Journal - October 21, 2013 Category: Cardiology Authors: The ORIGIN Trial Investigators, Mellbin, Ryden, Riddle, Probstfield, Rosenstock, Diaz, Yusuf, Gerstein Tags: Disease management Source Type: research

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial
Conclusion The 1-year risk for death, reinfarction, or stroke did not relate to glycaemic variability in T2DM patients with AMI treated with insulin infusion.
Source: European Heart Journal - February 1, 2013 Category: Cardiology Authors: Mellbin, L. G., Malmberg, K., Ryden, L., Wedel, H., Vestberg, D., Lind, M. Tags: Coronary artery disease Source Type: research